{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:43:01Z","timestamp":1787726581327,"version":"build-2784847793"},"reference-count":41,"publisher":"The Endocrine Society","issue":"6","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Patients with multiple endocrine neoplasia type 1 (MEN1) are genetically predisposed to developing tumors of the parathyroid, pancreas, and anterior pituitary. While widespread genetic testing has increased early diagnoses, the value of radiological surveillance for pituitary adenomas in these patients remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the impact of pituitary magnetic resonance imaging (MRI) findings on patient management in MEN1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective longitudinal cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>NIH Clinical Center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Genetically confirmed MEN1 evaluated between 1977 and September 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measures<\/jats:title>\n                    <jats:p>Cumulative proportion and rate of intervention for nonfunctional adenomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three hundred twenty patients with a mean follow-up duration of 14 \u00b1 12 years were identified. One hundred eighty-two out of 320 patients (57%) had pituitary adenomas, of whom 95\/182 (52%) had nonfunctional adenomas. All patients with adenoma had biochemical evaluation at the time of pituitary MRI. There were 21\/95 (22%) patients with nonfunctional adenomas that needed an intervention throughout their follow-up. The rate of intervention per 100 patient-years for nonfunctional adenomas was 3.1% (confidence interval 2.0-4.7%). All patients with nonfunctional adenoma who required an intervention reported symptoms or had an abnormal pituitary function test. Tumor volume of 38\/48 (79%) nonfunctional adenomas followed over a mean of 8.3 \u00b1 6.1 years remained stable. Only 42\/518 (8.1%) MRIs for nonfunctional adenomas were prompted by clinical or biochemical abnormalities. Individualized imaging could have avoided approximately 4 MRIs per patient with nonfunctional microadenoma over their follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In an overwhelming majority of patients with MEN1, radiological surveillance for nonfunctional pituitary adenomas offers minimal added benefit beyond patient-reported symptoms and pituitary function testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf704","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:26:14Z","timestamp":1767702374000},"page":"1575-1583","source":"Crossref","is-referenced-by-count":1,"title":["Radiological Surveillance for Pituitary Adenomas in Multiple Endocrine Neoplasia Type 1: A Longitudinal Cohort Study"],"prefix":"10.1210","volume":"111","author":[{"given":"Yetunde B","family":"Omotosho","sequence":"first","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayan U","family":"Vikram","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C","family":"Wright","sequence":"additional","affiliation":[{"name":"Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata","family":"Dola","sequence":"additional","affiliation":[{"name":"National Institutes of Health Clinical Center, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Abbas","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Tora","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bliss","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Cochran","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl F","family":"Pieper","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University School of Medicine , Durham, NC 27710 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-4756","authenticated-orcid":false,"given":"Prashant","family":"Chittiboina","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit for Pituitary and Inheritable Diseases, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee S","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7806-706X","authenticated-orcid":false,"given":"William F","family":"Simonds","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Biassou","sequence":"additional","affiliation":[{"name":"National Institutes of Health Clinical Center, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-3340","authenticated-orcid":false,"given":"Smita","family":"Jha","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20814 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"2","key":"2026051819565436100_dgaf704-B1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: latest insights","volume":"42","author":"Brandi","year":"2021","journal-title":"Endocr Rev"},{"issue":"5311","key":"2026051819565436100_dgaf704-B2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"7","key":"2026051819565436100_dgaf704-B3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","article-title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1","volume":"6","author":"Lemmens","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"Suppl 2","key":"2026051819565436100_dgaf704-B4","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.4103\/2230-8210.104058","article-title":"Multiple endocrine neoplasia type 1","volume":"16","author":"Thakker","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"issue":"9","key":"2026051819565436100_dgaf704-B5","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026051819565436100_dgaf704-B6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-8587(25)00119-6","article-title":"Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice","volume":"13","author":"Brandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026051819565436100_dgaf704-B7","doi-asserted-by":"crossref","first-page":"bvaa205","DOI":"10.1210\/jendso\/bvaa205","article-title":"Pituitary neoplasm nomenclature workshop: does adenoma stand the test of time?","volume":"5","author":"Ho","year":"2021","journal-title":"J Endocr Soc"},{"key":"2026051819565436100_dgaf704-B8","doi-asserted-by":"crossref","first-page":"1427821","DOI":"10.3389\/fendo.2024.1427821","article-title":"Long term outcomes of pituitary adenomas in multiple endocrine neoplasia type 1: a nationwide study","volume":"15","author":"Vald\u00e9s","year":"2024","journal-title":"Front Endocrinol"},{"issue":"4","key":"2026051819565436100_dgaf704-B9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3171\/2020.1.JNS193538","article-title":"Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience","volume":"134","author":"Cohen-Cohen","year":"2020","journal-title":"J Neurosurg"},{"issue":"4","key":"2026051819565436100_dgaf704-B10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.mric.2017.06.006","article-title":"Gadolinium-based contrast agents: associated adverse reactions","volume":"25","author":"Ramalho","year":"2017","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"4","key":"2026051819565436100_dgaf704-B11","doi-asserted-by":"crossref","first-page":"bvaa021","DOI":"10.1210\/jendso\/bvaa021","article-title":"Presenting features in 269 patients with clinically nonfunctioning pituitary adenomas enrolled in a prospective study","volume":"4","author":"Freda","year":"2020","journal-title":"J Endocr Soc"},{"issue":"4","key":"2026051819565436100_dgaf704-B12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0889-8529(05)70279-6","article-title":"Pituitary incidentalomas","volume":"26","author":"Molitch","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2026051819565436100_dgaf704-B13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41574-023-00949-7","article-title":"Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 2, specific diseases","volume":"20","author":"Korbonits","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2026051819565436100_dgaf704-B14","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1210\/JC.2015-2015","article-title":"Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG)","volume":"100","author":"de Laat","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026051819565436100_dgaf704-B15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11102-019-00939-x","article-title":"Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China","volume":"22","author":"Wu","year":"2019","journal-title":"Pituitary"},{"issue":"6","key":"2026051819565436100_dgaf704-B16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/EJE-21-0630","article-title":"Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study","volume":"185","author":"Le Bras","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026051819565436100_dgaf704-B17","doi-asserted-by":"crossref","first-page":"bvac001","DOI":"10.1210\/jendso\/bvac001","article-title":"MEN1 surveillance guidelines: time to (re)think?","volume":"6","author":"Newey","year":"2022","journal-title":"J Endocr Soc"},{"issue":"2","key":"2026051819565436100_dgaf704-B18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"2026051819565436100_dgaf704-B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"446","key":"2026051819565436100_dgaf704-B20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2026051819565436100_dgaf704-B21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/M22-1728","article-title":"Long-term changes in the size of pituitary microadenomas","volume":"176","author":"Hordejuk","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026051819565436100_dgaf704-B22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 Multicenter Study","volume":"87","author":"Verg\u00e8s","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051819565436100_dgaf704-B23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6061\/clinics\/2012(Sup01)09","article-title":"Pituitary tumors in patients with MEN1 syndrome","volume":"67","author":"Syro","year":"2012","journal-title":"Clinics"},{"issue":"7","key":"2026051819565436100_dgaf704-B24","first-page":"2642","article-title":"Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred","volume":"81","author":"Burgess","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026051819565436100_dgaf704-B25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2265.2007.02990.x","article-title":"What is the natural history of nonoperated nonfunctioning pituitary adenomas?","volume":"67","author":"Karavitaki","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2026051819565436100_dgaf704-B26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/eje.1.02334","article-title":"The natural course of non-functioning pituitary macroadenomas","volume":"156","author":"Dekkers","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026051819565436100_dgaf704-B27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11102-005-1757-1","article-title":"Retrospective multicentric study of pituitary incidentalomas","volume":"7","author":"Day","year":"2004","journal-title":"Pituitary"},{"issue":"1","key":"2026051819565436100_dgaf704-B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2265.1999.00748.x","article-title":"Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study","volume":"51","author":"Feldkamp","year":"1999","journal-title":"Clin Endocrinol"},{"issue":"8","key":"2026051819565436100_dgaf704-B29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2176\/nmc.39.592","article-title":"Long-term magnetic resonance imaging follow-up of asymptomatic sellar tumors.\u2014their natural history and surgical indications","volume":"39","author":"Igarashi","year":"1999","journal-title":"Neurol Med Chir"},{"issue":"10","key":"2026051819565436100_dgaf704-B30","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2026051819565436100_dgaf704-B31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cen.12860","article-title":"Clinical outcomes in patients with nonfunctioning pituitary adenomas managed conservatively","volume":"83","author":"Sam","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2026051819565436100_dgaf704-B32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-89-3-345","article-title":"Acromegaly and galactorrhea-amenorrhea with two pituitary adenomas secreting growth hormone or prolactin. A case report","volume":"89","author":"Tolis","year":"1978","journal-title":"Ann Intern Med"},{"issue":"3","key":"2026051819565436100_dgaf704-B33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1507\/endocrj.42.331","article-title":"Two different pituitary adenomas in a patient with multiple endocrine neoplasia type 1 associated with growth hormone-releasing hormone-producing pancreatic tumor","volume":"42","author":"Shintani","year":"1995","journal-title":"Endocr J"},{"issue":"1","key":"2026051819565436100_dgaf704-B34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12022-007-0008-6","article-title":"Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology","volume":"18","author":"Al Brahim","year":"2007","journal-title":"Endocr Pathol"},{"issue":"11","key":"2026051819565436100_dgaf704-B35","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1210\/en.2012-1675","article-title":"Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors","volume":"153","author":"Walls","year":"2012","journal-title":"Endocrinology"},{"issue":"1","key":"2026051819565436100_dgaf704-B36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/jc.2004-1373","article-title":"Gonadotroph tumor associated with multiple endocrine neoplasia type 1","volume":"90","author":"Benito","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026051819565436100_dgaf704-B37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ando.2012.03.001","article-title":"Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment","volume":"73","author":"Philippon","year":"2012","journal-title":"Ann Endocrinol"},{"key":"2026051819565436100_dgaf704-B38","doi-asserted-by":"crossref","first-page":"100242","DOI":"10.1016\/j.ejro.2020.100242","article-title":"Malignancy course of pituitary adenoma in MEN1 syndrome: clinical-neuroradiological signs","volume":"7","author":"Incandela","year":"2020","journal-title":"Eur J Radiol Open"},{"issue":"2","key":"2026051819565436100_dgaf704-B39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.humpath.2008.06.013","article-title":"Multiple endocrine neoplasia type 1\u2013associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example","volume":"40","author":"Scheithauer","year":"2009","journal-title":"Hum Pathol"},{"issue":"1","key":"2026051819565436100_dgaf704-B40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2265.2006.02697.x","article-title":"Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN-1)","volume":"66","author":"Gordon","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2026051819565436100_dgaf704-B41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41574-023-00948-8","article-title":"Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: part 1, general recommendations","volume":"20","author":"Korbonits","year":"2024","journal-title":"Nat Rev Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf704\/66288866\/dgaf704.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/6\/1575\/66288866\/dgaf704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/6\/1575\/66288866\/dgaf704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:57:02Z","timestamp":1779148622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/6\/1575\/8416067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf704","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,7]]}}}